In the past few years there have been numerous reports of central nervous system (CNS) manifestations of third stage Lyme borreliosis (LB), extending the neurological spectrum.1 Neuropsychiatric manifestations resembling general paresis in third stage syphilis have been delineated by Pachner and Steere as well as focal CNS lesions appearing months or years after the initial infection.2 Already in 1985 Ackermann et al coined the term "Progressive Borrelia Encephalomyelitis"3 indicating a chronic third stage borrelial infection of the brain3-5 and spinal cord3 67 sometimes showing a remitting, sometimes a progressive course of disease.3 614 In a few instances the disease seemed to be indistinguishable from multiple sclerosis.9 15 16 In this respect conflicting results have been presented by several authors.9 15 17 18 Controversy has been accentuated by Gay and Dick's hypothesis of a possible spirochetal origin of multiple sclerosis.17 19 23 However Only patients originating from the province of Tyrol were eligible. Fifty-seven patients had died, were not residents of, or had moved away from our province, 42 refused to take part in the study. Twenty-seven could not be traced for a variety of reasons. In seven instances the sera were lost, thus a remaining 106 patients could be included in this study. All patients and control persons were visited at home. As a control, usually a close family member, living in the same household, or within the vicinity, was chosen. For three patients, living in an institution for aged people no controls were available; thus their number was 103.
The patients and controls had to fill out a short questionnaire dealing with their disease, living habits, previous tickbites and therapy. From all persons 10 ml blood was drawn for serological examination. This was done at the Hygiene Institute of the University of Vienna, by means of ELISA technique.
The ELISA test was performed as described elsewhere.2" Briefly, sonicated B. burgdorferi B31 at a concentration of 10*g/ml was coated onto Nunc microtitre plates by overnight incubation in a pH 9-6 carbonate buffer. Subsequent incubations were performed with human sera, peroxidaseconjugated goat anti-human antibody, and substrate, with washes between the incubation. Colour was read by SLT (27.4%) were suffering from a chronic progressive course of disease, whereas 67 (63.2%) had a relapsing/remitting form of multiple sclerosis. In 10 patients (9-4%) classification was not possible. Mean borrelia antibody level (IgG) in chronic progressive patients was 3-7 SD 1-3 EU. Their controls had a mean of 3-8 SD 1 0 EU. In patients with relapsing/remitting multiple sclerosis a mean of 3-4 SD 0 9 EU was found and a mean of 3-7 SD 10 EU in their.corresponding controls. Comparing the titres of patients (both chronic progressive and relapsing/remitting) with their corresponding controls and titres of chronic progressive patients with those of relapsing/remitting patients, no significant difference could be found.
Median duration of illness was 10 years, range < 1 year to 43 years. Positive correlation could neither be found between duration of illness and borrelia antibody titre (r = 0.19) nor between age and antibody titre (r = 0-21).
Twenty eight (= 26.4%) multiple sclerosis patients and 32 (= 31-1 %) controls remembered a tick bite; no difference, however, could be found between the antibody level of the tick bite positive and negative persons (X = 3-57, SD 1-24 versus X = 3M64, SD 0-92 EU). Of those with antibody level above threshold (>4.5 EU) 3/15 multiple sclerosis patients and 9/27 controls had a history of tick bite.
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